Literature DB >> 30515959

In Vitro and In Vivo Proteomic Comparison of Human Neural Progenitor Cell-Induced Photoreceptor Survival.

Melissa K Jones1, Bin Lu1, Dawn Zhaohui Chen2,3, Weston R Spivia2, Augustus T Mercado1, Alexander V Ljubimov1,3, Clive N Svendsen1, Jennifer E Van Eyk2,3, Shaomei Wang1,3.   

Abstract

Retinal degenerative diseases lead to blindness with few treatments. Various cell-based therapies are aimed to slow the progression of vision loss by preserving light-sensing photoreceptor cells. A subretinal injection of human neural progenitor cells (hNPCs) into the Royal College of Surgeons (RCS) rat model of retinal degeneration has aided in photoreceptor survival, though the mechanisms are mainly unknown. Identifying the retinal proteomic changes that occur following hNPC treatment leads to better understanding of neuroprotection. To mimic the retinal environment following hNPC injection, a co-culture system of retinas and hNPCs is developed. Less cell death occurs in RCS retinal tissue co-cultured with hNPCs than in retinas cultured alone, suggesting that hNPCs provide retinal protection in vitro. Comparison of ex vivo and in vivo retinas identifies nuclear factor (erythroid-derived 2)-like 2 (NRF2) mediated oxidative response signaling as an hNPC-induced pathway. This is the first study to compare proteomic changes following treatment with hNPCs in both an ex vivo and in vivo environment, further allowing the use of ex vivo modeling for mechanisms of retinal preservation. Elucidation of the protein changes in the retina following hNPC treatment may lead to the discovery of mechanisms of photoreceptor survival and its therapeutic for clinical applications.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  human neural progenitor cells; neuroprotection; retinal degeneration; stem cells; transplantationzzm321990

Mesh:

Substances:

Year:  2019        PMID: 30515959      PMCID: PMC6422354          DOI: 10.1002/pmic.201800213

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  52 in total

1.  Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.

Authors:  Lee E Goldstein; Julien A Muffat; Robert A Cherny; Robert D Moir; Maria H Ericsson; Xudong Huang; Christine Mavros; Jennifer A Coccia; Kyle Y Faget; Karlotta A Fitch; Colin L Masters; Rudolph E Tanzi; Leo T Chylack; Ashley I Bush
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

Review 2.  Age-related macular degeneration.

Authors:  Laurence S Lim; Paul Mitchell; Johanna M Seddon; Frank G Holz; Tien Y Wong
Journal:  Lancet       Date:  2012-05-05       Impact factor: 79.321

3.  Retrograde neurotrophic signaling in rat retinal ganglion cells is transmitted via the ERK5 but not the ERK1/2 pathway.

Authors:  Christian van Oterendorp; Stavros Sgouris; Nils Schallner; Julia Biermann; Wolf A Lagrèze
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-03       Impact factor: 4.799

4.  Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

Authors:  Cliona Stack; Daniel Ho; Elizabeth Wille; Noel Y Calingasan; Charlotte Williams; Karen Liby; Michael Sporn; Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-03-23       Impact factor: 7.376

5.  Neurotrophins use the Erk5 pathway to mediate a retrograde survival response.

Authors:  F L Watson; H M Heerssen; A Bhattacharyya; L Klesse; M Z Lin; R A Segal
Journal:  Nat Neurosci       Date:  2001-10       Impact factor: 24.884

6.  Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model.

Authors:  Hyunjin Vincent Kim; Hye Yun Kim; Hanna Y Ehrlich; Seon Young Choi; Dong Jin Kim; YoungSoo Kim
Journal:  Amyloid       Date:  2012-12-19       Impact factor: 7.141

Review 7.  Liver X receptors in lipid metabolism: opportunities for drug discovery.

Authors:  Cynthia Hong; Peter Tontonoz
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

8.  Multi-modal proteomic analysis of retinal protein expression alterations in a rat model of diabetic retinopathy.

Authors:  Heather D VanGuilder; Georgina V Bixler; Lydia Kutzler; Robert M Brucklacher; Sarah K Bronson; Scot R Kimball; Willard M Freeman
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

9.  Protection of visual functions by human neural progenitors in a rat model of retinal disease.

Authors:  David M Gamm; Shaomei Wang; Bin Lu; Sergei Girman; Toby Holmes; Nicholas Bischoff; Rebecca L Shearer; Yves Sauvé; Elizabeth Capowski; Clive N Svendsen; Raymond D Lund
Journal:  PLoS One       Date:  2007-03-28       Impact factor: 3.240

10.  Proteomics-based identification and validation of novel plasma biomarkers phospholipid transfer protein and mannan-binding lectin serine protease-1 in age-related macular degeneration.

Authors:  Hye-Jung Kim; Seong Joon Ahn; Se Joon Woo; Hye Kyoung Hong; Eui Jin Suh; Jeeyun Ahn; Ji Hyun Park; Na-Kyung Ryoo; Ji Eun Lee; Ki Woong Kim; Kyu Hyung Park; Cheolju Lee
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

View more
  3 in total

1.  A stem cell journey in ophthalmology: From the bench to the clinic.

Authors:  Ingrid W Caras; Lila R Collins; Abla A Creasey
Journal:  Stem Cells Transl Med       Date:  2021-09-13       Impact factor: 6.940

2.  Retinal Neuroprotective Effect of Mesenchymal Stem Cells Secretome Through Modulation of Oxidative Stress, Autophagy, and Programmed Cell Death.

Authors:  Ricardo Usategui-Martín; Kevin Puertas-Neyra; Nadia Galindo-Cabello; Leticia A Hernández-Rodríguez; Fernando González-Pérez; José Carlos Rodríguez-Cabello; Rogelio González-Sarmiento; José Carlos Pastor; Ivan Fernandez-Bueno
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-04-01       Impact factor: 4.925

3.  Human Mesenchymal Stem Cell Secretome Exhibits a Neuroprotective Effect over In Vitro Retinal Photoreceptor Degeneration.

Authors:  Ricardo Usategui-Martín; Kevin Puertas-Neyra; María-Teresa García-Gutiérrez; Manuel Fuentes; José Carlos Pastor; Ivan Fernandez-Bueno
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-13       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.